Upregulation of HER-2/neu by ovarian ablation: Results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients

Breast Cancer Research and Treatment

Volumn 80, Issue 3, 2003, Pages 245-255

  Lüftner, Diana ^a   Jung, A ^a   Schmid, P ^a   Geppert, R ^a   Kienle, E ^b   Wernecke, K D ^c   Possinger, K ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Leuprorelin; Ovarian ablation; Serum HER 2 neu

Indexed keywords

CA 27-29 ANTIGEN; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; METHOTREXATE; PROGESTERONE RECEPTOR; TRENATONE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LEUPROLIDE; METHOTREXATE; MIDDLE AGED; OVARY; RECEPTOR, ERBB-2; TREATMENT OUTCOME; UP-REGULATION;

EID: 17344374991     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024911625339     Document Type: Article

References (52)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
2. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 198
3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990
4. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
6. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986
7. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984
8. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985
9. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720, 1991
10. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711, 2001
11. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59: 1196-1201, 1999
12. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749, 2001
13. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F, De Bortoli M: AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 19: 280-288, 2000
14. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995
15. Kobayashi S, Iwase H, Itoh Y, Fukuoka H, Yamashita H, Kuzushima T, Iwata H, Masaoka A, Kimura N: Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res 83: 859-865, 1992
16. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7-12, 1998
17. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303, 1991
18. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, Pounds GW, Vendely P, Owens MA, Pandian MR: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer I 84: 1279-1282, 1992
19. Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M: Oestrogen and epidermal growth factor downregulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 70: 1095-1101, 1994
20. Bates NP, Hurst HC: An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15: 473-481, 1997
21. Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318-321, 1992
22. Read LD, Keith Jr D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990
23. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006, 1990
24. Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, Colnaghi MI, Menard S: Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol 155: 1543-1547, 1999
25. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344: 783-792, 2001
26. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000
27. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17: 1974-1982, 1999
28. Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Possinger K: Cyclophosphamide, methotrexate, and fluorouracil versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate). Anticancer Res 22: 2325-2332, 2002
29. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL: Automated assay for HER-2/neu in serum. Clin Chem 46: 175-182, 2000
30. Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, Yeung KK, Chan DW, Schwartz MK, Allard WJ: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21: 1465-1470, 2001
31. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K, Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 37: 355-363, 2001
32. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K: Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20: 5077-5082, 2000
33. Yamazaki I, Okada H: A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocrinol Japon 27: 593-605, 1980
34. Abraham GE, Odell WD, Swerdloff RS, Hopper K: Simultaneous radioimmunoassay of plasma FSH, LH, progesterone, 17-hydroxyprogesterone, and estradiol-17 beta during the menstrual cycle. J Clin Endocr Metab 34: 312-318, 1972
35. Ratcliffe WA, Carter GD, Dowsett M, Hillier SG, Middle JG, Reed MJ: Oestradiol assays: applications and guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 25(Pt 5): 466-483, 1988
36. Storring PL, Bangham DR, Cotes PM, Gaines RE, Jeffcoate SL: The international reference preparation of human pituitary luteinizing hormone, for immunoassay. Acta Endocrinol-Cop 88: 250-259, 1978
37. Brunner E: Nichtparametrische Analyse longitudinaler Daten. Oldenburg Verlag, München, Wien, Oldenburg, 2002
38. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12 (Suppl 1): S15-S19, 2001
39. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38: 96-104, 2001
40. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE: erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56: 522-528, 1994
41. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C: Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560-567, 1995
42. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC: Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19: 490-497, 2000
43. Bagli L, Dittadi R, Zancan M, Panzini I, Monti F, Ravaioli A: HER-2/neu serum levels and menopausal status. Int J Biol Marker 16: 69-70, 2001
44. Meden H, Mielke S, Marx D, Wuttke W, Kuhn W: Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17: 3075-3077, 1997
45. Mielke S, Meden H, Raab T, Wuttke W, Kuhn W: Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res 17: 3125-3127, 1997
46. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians Jr FH, Hynan L, Ashfaq R: Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116: 495-503, 2001
47. Lüftner D, Henschke P, Kafka A, Anagnostopoulos I, Wiechen K, Geppert R, Stein H, Wernecke KD, Kreienberg R, Possinger K: Discordances between different methods of HER-2/neu evaluation in breast cancer - a question of standardization, automation and timing. Tumor Biol (in press)
48. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ: Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 8: 751-756, 1997
49. Hagen AA, Hrushesky WJ: Menstrual timing of breast cancer surgery. Am J Surg 175: 245-261, 1998
50. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 343: 1545-1547, 1994
51. Oliver DJ, Ingram DM: Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. Eur J Cancer 31A: 325-328, 1995
52. Fentiman IS, Gregory WM, Richards MA: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 344: 402, 1994